Metrics as of 10/14/2026, 08:28 PM (Berlin time), refresh in progress.
ADC Therapeutics Stock
ADC Therapeutics S.A.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- CEO
- Ameet Mallik
- Employees
- 191
- Market cap
- $179 M
- IPO
- 18/05/2020
ADC Therapeutics S.A. is a commercial-stage biotechnology company headquartered in Epalinges, Switzerland. The company focuses on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is currently being evaluated in multiple…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
ADC Therapeutics stock: price history
1D
-6.0%
1W
-19.1%
1M
+33.3%
6M
-67.3%
YTD
-60.3%
1Y
-66.1%
2Y
-56.5%
5Y
-94.5%
10Y
–
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~28% stronger price swings than usual
Ask the agents about ADC Therapeutics
Analyst assessment of ADC Therapeutics
PRICE TARGET LOW
US$2.00
CONSENSUS
US$3.50
MEDIAN
US$3.50
PRICE TARGET HIGH
US$5.00
0
STRONG BUY
5
BUY
6
HOLD
1
SELL
0
STRONG SELL
12
TOTAL · Hold
As of: 17/08/2026
ADC Therapeutics stock metrics
P/E
-2.11
P/B
-0.95
EV/EBITDA
-4.3
RETURN ON EQUITY
7.3%
NET MARGIN
-86.1%
DEBT/EQUITY
-1.83
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
76.5%
FLOAT SHARES
97,245,278
AVG. DAILY VOLUME (30D)
1,667,592
Insider transactions (SEC)
MALLIK AMEET
Carmona Jose
GRAHAM PETER J
Zaki Mohamed
Coughlin Timothy
Institutional holders
Comparable stocks
Frequently asked questions about ADC Therapeutics stock
What does ADC Therapeutics do?
ADC Therapeutics S.A. is a company in the Healthcare sector, Biotechnology industry, headquartered in Switzerland.
The CEO is Ameet Mallik, the company employs around 191 people.
The IPO was on 18/05/2020; the stock trades on NYSE under the ticker ADCT.
What do analysts say about ADC Therapeutics stock?
12 analysts rate the stock, the consensus is Hold (as of 17/08/2026).
The average price target is US$3.50, ranging from US$2.00 to US$5.00, with a median of US$3.50.
This is an external assessment, not a statement by Market Jury.
When does ADC Therapeutics report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly 28% stronger than usual.
Does ADC Therapeutics pay a dividend?
No, ADC Therapeutics currently does not pay a dividend.
Which stocks are comparable to ADC Therapeutics?
Comparable stocks include BeOne Medicines, Pharvaris, Idorsia, Basilea Pharmaceutica, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and argenx.
How can I get ADC Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess ADC Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.